Other ongoing studies include a TCR-T therapy targeting EBV, developed by TCRCure Biopharma, for metastatic head and neck cancer and cervical cancer, as well as TC-510, developed by TCR2 Therapeutics, which targets mesothelin for the treatment of late-stage mesothelin-expressing cancers (16). This evidence concerns the gene MSLN and head and neck cancer.